<DOC>
	<DOC>NCT00892021</DOC>
	<brief_summary>This study will evaluate the safety of multiple doses of NSA-789 in subjects with schizophrenia or schizoaffective disorder. This study will also assess how NSA-789 is absorbed and eliminated, and its effect, if any, on the brain.</brief_summary>
	<brief_title>Study Evaluating the Effects of Multiple Doses of NSA-789 in Subjects With Schizophrenia or Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Inclusion: Men or women of non childbearing potential (WONCBP) aged 18 to 50 years, inclusive. Currently under the care of a physician for psychiatric illness. Clinical diagnosis of schizophrenia or schizo affective disorder in the opinion of the study psychiatrist based on review of all available clinical data. Exclusion: Any unstable medical or psychiatric condition, which may prevent the successful and safe completion of the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>